Present strategies aimed to target and manipulate RNA in living cells mainly rely on the use of antisense oligonucleotides (ASO) or engineered RNA binding proteins (RBP). Although ASO therapies have been shown great promise in eliminating pathogenic transcripts or modulating RBP binding, they are synthetic in construction and thus cannot be encoded within DNA. This complicates potential gene therapy strategies, which would rely on regular administration of ASOs throughout the lifetime of the patient. Furthermore, they are incapable of modulating the genetic sequence of RNA. Although engineered RBPs such as PUF proteins can be designed to recognize target transcripts and fused to RNA modifying effectors to allow for specific recognition and manipulation, these constructs require extensive protein engineering for each target and may prove to be laborious and costly. Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0in; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;}

Researchers at the University of California, Davis have developed a deep learning-based technology that analyzes facial images to distinguish seven human emotions.

Researchers at the University of California, Davis have developed microorganisms with increased alcohol tolerance by modifying the organisms’ pntAB locus through expression of one or both of its pntA/pntB genes.

Researchers at the University of California, Davis have developed a phased-locked loop coupled array system capable of generating phase shifts in phased array antenna systems - while minimizing signal losses.

The inventors have designed and tested Locked Nucleic Acid (LNA) Antisense Oligonucleotides (ASOs) targeting the SARS-CoV-2 Spike RNA and 5' leader of ORF1ab RNA and identified several hits that exhibit excellent on-target efficacy at 50-100 nM in decreasing viral RNA load (Spike and N RNAs) 48 hours post-infection in human Huh-7 cells, with no apparent toxicity. These LNA ASOs will serve as leads for testing of therapeutic targeting of SARS-CoV-2 in animal models, before possible assessment in human trials.

Brief description not available

Internet of Things ( IoT ) applications often analyze collected data using machine learning algorithms. As the amount of the data keeps increasing, many applications send the data to powerful systems, e.g., data centers, to run the learning algorithms . On the one hand, sending the original data is not desirable due to privacy and security concerns.On the other hand, many machine learning models may require unencrypted ( plaintext ) data, e.g., original images , to train models and perform inference . When offloading theses computation tasks, sensitive information may be exposed to the untrustworthy cloud system which is susceptible to internal and external attacks . In many IoT systems , the learning procedure should be performed with the data that is held by a large number of user devices at the edge of Internet . These users may be unwilling to share the original data with the cloud and other users if security concerns cannot be addressed.

Tumor Treating Fields (TTFields) is a tissue ablation technology that inhibits the uncontrolled growth of cells in the body, such as cancer cells, with non-contact electromagnetic fields. Electrodes attached to the skin, such as on a shaved skull, deliver the electromagnetic fields. In order to achieve a therapeutic effect, this minimally invasive cancer treatment must be delivered continuously, over a long period of time. The therapy is monitored with MRI imaging, every one to three months.In between MRI scans, the effects of treatment can be monitored through additional electrodes attached to precise locations on the skin. For example, when treating the brain, electrodes tightly attached to the skull can detect changes in the complex electrical impedance of the monitored tissue. Data collected from the electrodes can be also used to control and optimize treatment parameters.